可信度指数的特征。

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Piero Quatto, Enrico Ripamonti, Donata Marasini
{"title":"可信度指数的特征。","authors":"Piero Quatto, Enrico Ripamonti, Donata Marasini","doi":"10.1080/10543406.2025.2456170","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, the role of the <i>p</i>-value in applied research has been heavily scrutinized. Several new proposals have been put forward from a Bayesian viewpoint, including the analysis of credibility. By using the reverse Bayes theorem, and reasoning in terms of subverting the significance or the non-significance denoted by the <i>p</i>-value, this analysis provides the credibility, in a Bayesian sense, of an experimental result. We discuss a normalized indicator of credibility, namely <math><mi>C</mi></math>, a variant of the index <math><mover><mi>C</mi><mo>˜</mo></mover></math> (Quatto et al. J. Biopharm. Stat. 32, 308-329, 2022). This can be used to assess the degree of credibility of experimental results and can also be compared with a fixed threshold. The index is extended to the case of one-sided hypotheses. A simulation study is conducted to empirically assess the behavior of the index <math><mi>C</mi></math>. Two illustrative examples in the contexts of pharmacotherapy for COVID-19 and heart failure are presented. We then propose adopting the credibility index for meta-analyses, in which it can provide a suitable diagnostic value for modeling fixed and random effects.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-16"},"PeriodicalIF":1.2000,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characterization of a credibility index.\",\"authors\":\"Piero Quatto, Enrico Ripamonti, Donata Marasini\",\"doi\":\"10.1080/10543406.2025.2456170\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In recent years, the role of the <i>p</i>-value in applied research has been heavily scrutinized. Several new proposals have been put forward from a Bayesian viewpoint, including the analysis of credibility. By using the reverse Bayes theorem, and reasoning in terms of subverting the significance or the non-significance denoted by the <i>p</i>-value, this analysis provides the credibility, in a Bayesian sense, of an experimental result. We discuss a normalized indicator of credibility, namely <math><mi>C</mi></math>, a variant of the index <math><mover><mi>C</mi><mo>˜</mo></mover></math> (Quatto et al. J. Biopharm. Stat. 32, 308-329, 2022). This can be used to assess the degree of credibility of experimental results and can also be compared with a fixed threshold. The index is extended to the case of one-sided hypotheses. A simulation study is conducted to empirically assess the behavior of the index <math><mi>C</mi></math>. Two illustrative examples in the contexts of pharmacotherapy for COVID-19 and heart failure are presented. We then propose adopting the credibility index for meta-analyses, in which it can provide a suitable diagnostic value for modeling fixed and random effects.</p>\",\"PeriodicalId\":54870,\"journal\":{\"name\":\"Journal of Biopharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"1-16\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-02-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biopharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10543406.2025.2456170\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2456170","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

近年来,p值在应用研究中的作用受到了严格的审查。从贝叶斯的角度提出了一些新的建议,包括可信性分析。通过使用反向贝叶斯定理,并在颠覆p值表示的显著性或非显著性方面进行推理,该分析在贝叶斯意义上提供了实验结果的可信度。我们讨论了一个标准化的可信度指标,即C,指数C ~ (Quatto等)的变体。j . Biopharm。Stat. 32, 308- 329,2022)。这可以用来评估实验结果的可信度,也可以与固定阈值进行比较。该指数推广到单侧假设的情况。本文进行了一项模拟研究,以经验性评估指数c的行为。本文给出了COVID-19药物治疗和心力衰竭背景下的两个说明性示例。然后,我们建议采用可信度指标进行meta分析,它可以为固定效应和随机效应的建模提供合适的诊断值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Characterization of a credibility index.

In recent years, the role of the p-value in applied research has been heavily scrutinized. Several new proposals have been put forward from a Bayesian viewpoint, including the analysis of credibility. By using the reverse Bayes theorem, and reasoning in terms of subverting the significance or the non-significance denoted by the p-value, this analysis provides the credibility, in a Bayesian sense, of an experimental result. We discuss a normalized indicator of credibility, namely C, a variant of the index C˜ (Quatto et al. J. Biopharm. Stat. 32, 308-329, 2022). This can be used to assess the degree of credibility of experimental results and can also be compared with a fixed threshold. The index is extended to the case of one-sided hypotheses. A simulation study is conducted to empirically assess the behavior of the index C. Two illustrative examples in the contexts of pharmacotherapy for COVID-19 and heart failure are presented. We then propose adopting the credibility index for meta-analyses, in which it can provide a suitable diagnostic value for modeling fixed and random effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信